erus BioSciences(CHRS) - 2025 Q4 - Annual Results

Financial Results Presentation - Coherus Oncology, Inc. will present preliminary unaudited net revenues for the quarter and fiscal year ended December 31, 2025, at the 43rd Annual J.P. Morgan Healthcare Conference[4] - The financial closing procedures for the quarter and fiscal year ended December 31, 2025, are not yet complete, which may lead to significant changes in the preliminary results[6] - The independent registered public accounting firm has not reviewed or audited the financial results presented in this announcement[6] Forward-Looking Statements and Risks - Forward-looking statements include projected revenue growth for LOQTORZI, which involves substantial risks and uncertainties[7] - The company highlights risks related to market acceptance of its products by healthcare providers and patients, as well as potential litigation risks[7]